Inactive Instrument

Alzheon, Inc.

Equities

ALZH

US00168L1017

Biotechnology & Medical Research

Alzheon Appoints Jean-Pierre Garnier as Chairman of Board of Directors

December 10, 2015 at 06:30 pm IST

Alzheon, Inc. announced that Jean-Pierre Garnier, PhD, has been appointed Chairman of the Board of Directors of the company. Dr. Garnier brings world-class expertise and global perspective to help build Alzheon into a leading clinical-stage Alzheimer's company. Currently, Dr. Garnier is Chairman of the Board of Directors for the Swiss biopharmaceutical company Actelion.

Latest news about Alzheon, Inc.

Alzheon, Inc. Announces First Patient Dosed in Long-Term Extension of APOLLOE4 Phase 3 Trial of Oral ALZ-801/Valiltramiprosate and Launches 52-Week Extension of Phase 2 Biomarker Trial in Patients with Early Alzheimer's Disease	30/04	CI
Alzheon, Inc. announced a financing transaction	27/02	CI
Alzheon Promotes Glenn E. Pauly to Chief Commercial Officer	05/12	CI
Alzheon, Inc. to Present Biomarker, Brain Preservation, and Clinical Results from Pivotal Program of Oral ALZ-801/Valiltramiprosate at 16th Annual Clinical Trials in Alzheimer's Disease Conference	17/23/17	CI
Alzheon To Present Pivotal Program of Oral ALZ-801/Valiltramiprosate at Singularity Conference, Goldman Sachs Alzheimer?s Disease Day, and BIO Investor Forum	26/23/26	CI
Alzheon Reports Biomarker, Brain Preservation and Clinical Benefits Following 24 Months of Treatment in Phase 2 Trial of Oral ALZ-801 in Patients with Early Alzheimer's Disease	13/23/13	CI
Alzheon to Present Baseline Imaging Characteristics from Ongoing APOLLOE4 Phase 3 Trial of Oral Tablet	11/23/11	CI
Alzheon, Inc. to Present Baseline Imaging Characteristics from Ongoing APOLLOE4 Phase 3 Trial of Oral Tablet ALZ-801 (Valiltramiprosate) and Results of Phase 2 Biomarker Study At American Academy of Neurology Conference in Boston	18/23/18	CI
Alzheon, IncAnnounces Early Completion of Enrollment of APOLLOE4 Phase 3 Clinical Trial Evaluating Oral ALZ-801 (Valiltramiprosate) in APOE4/4 Homozygotes with Early Alzheimer’s Disease	06/22/06	CI
Alzheon, Inc. announced that it expects to receive $50.004201 million in funding	30/22/30	CI
Alzheon, Inc. Reports Brain Preservation and Clinical Effects Following 12 Months of Treatment in Phase 2 Trial of Oral Alz-801 (Valiltramiprosate) in Patients with Early Alzheimer’S Disease	20/22/20	CI
Alzheon, Inc Appoints Glenn Pauly as Head of Commercial	20/22/20	CI
Alzheon, Inc. to Present Industry-Leading Phase 2 Biomarker and Clinical Data with ALZ -801 (Valiltramiprosate) Oral Tablet At 2022 Alzheimer’S Association International Conference	26/22/26	CI
Alzheon, Inc. announced that it has received $50.000004 million in funding	14/22/14	CI
Alzheon to Present ALZ-801 (Valiltramiprosate) Phase 3 Program Update and Industry-Leading Disease Modifying Effects from Phase 2 Trial in Patients with Early Alzheimer’s Disease At AD/PD and NDDS Scientific Conferences	08/22/08	CI
Alzheon Reports Disease Modifying Effects from Phase 2 Biomarker Trial of Oral Tablet ALZ-801 (Valiltramiprosate) in Patients with Early Alzheimer’s Disease	08/22/08	CI
Alzheon to Present New Data from Ongoing Phase 2 Biomarker Trial of ALZ-801 Oral Tablet at Clinical Trials in Alzheimer?s Disease Conference	01/21/01	CI
Alzheon Appoints Adem Albayrak as Head of Operations	13/21/13	CI
Alzheon, Inc. Completes Patient Enrollment in Phase 2 Biomarker Trial of ALZ-801 Oral Tablet in APOE4 Carriers with Alzheimer’s Disease	23/21/23	CI
Alzheon, Inc. Announces Publication of Peer-Reviewed Scientific Demonstrates Central Role of Neurotoxic Soluble Amyloid Oligomers in Driving Alzheimer’s Pathogenesis	23/21/23	CI
Alzheon Announces First Patient Dosed in APOLLOE4 Phase 3 Trial of Oral ALZ-801 in Patients with Early Alzheimer’s Disease	04/21/04	CI
Alzheon, Inc. Partners with Institute of Organic Chemistry and Biochemistry to Develop First Alzheimer’s Diagnostic Assay for Measuring Neurotoxic Beta Amyloid Oligomers in Human Brain	04/21/04	CI
Alzheon CEO Presents Overview of Oral Anti-Amyloid Alz-801 Phase 3 Program at 9Th Neurodegenerative Drug Development Summit	24/21/24	CI
Alzheon, Inc. Announces Dosing of First Patient in ALZ-801 Phase 2 Biomarker Study in APOE4 Carriers with Early Alzheimer’S Disease	27/20/27	CI
Alzheon, Inc. announced that it expects to receive $50.000004 million in funding	14/20/14	CI

Chart Alzheon, Inc.

Duration

Period

More charts

Company Profile

Alzheon Inc is a United States-based clinical-stage biopharmaceutical company. The company is developing medicines for patients suffering from alzheimer's disease and other neurological and psychiatric disorders. The Company is focused on brain health, memory and aging and develops treatments for alzheimer's disease and other neurodegenerative disorders.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+51.85%	59.28B
LONZA GROUP AG	+41.42%	40.94B
IQVIA HOLDINGS INC.	-5.25%	40.17B
CELLTRION, INC.	-5.16%	28.69B
ICON PUBLIC LIMITED COMPANY	+12.79%	26.63B
ALNYLAM PHARMACEUTICALS, INC.	-20.18%	18.89B
MEDPACE HOLDINGS, INC.	+30.88%	12.46B
BIO-TECHNE CORPORATION	+0.61%	12.42B
UNITED THERAPEUTICS CORPORATION	+25.06%	12.26B

Other Biotechnology & Medical Research